Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant

Trial Profile

Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Sep 2017

At a glance

  • Drugs Romidepsin (Primary) ; Antithymocyte globulin; Busulfan; Fludarabine; Stem cell therapies
  • Indications Acute lymphoblastic leukaemia; Cutaneous T cell lymphoma; Myeloid leukaemia; Peripheral T-cell lymphoma; T cell prolymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 May 2016 Thymoglobulin has been added to treatment and duration of romidepsin by vein changed from over 1 hour to 4 hours.
    • 29 Oct 2015 Planned number of patients changed from 42 to 30, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top